Aliskiren

Circulation

Volumn 118, Issue 7, 2008, Pages 773-784

  Brown, Morris J ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Aliskiren; Renin; Renin inhibitor

Indexed keywords

ALISKIREN; ALISKIREN PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CELECOXIB; CIMETIDINE; CYTOCHROME P450; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DRUG METABOLITE; ENALAPRIL; HYDROCHLOROTHIAZIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; MEVINOLIN; NATRIURETIC FACTOR; PLACEBO; POTASSIUM SPARING DIURETIC AGENT; RAMIPRIL; RENIN; THIAZIDE DIURETIC AGENT; VALSARTAN; WARFARIN; AMIDE; ANTIHYPERTENSIVE AGENT; FUMARIC ACID DERIVATIVE;

ADD ON THERAPY; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DRUG URINE LEVEL; FOOD INTAKE; HEADACHE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; IC 50; IMMUNOASSAY; KIDNEY DYSFUNCTION; LOW DRUG DOSE; MONOTHERAPY; NEGATIVE FEEDBACK; OBESITY; OUTCOME ASSESSMENT; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RHINOPHARYNGITIS; RISK BENEFIT ANALYSIS; TREATMENT DURATION; TREATMENT RESPONSE; ARTICLE; BLOOD PRESSURE; DRUG ANTAGONISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

AMIDES; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; FUMARATES; HUMANS; HYPERTENSION; RENIN;

EID: 50349094508     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.108.787630     Document Type: Review

References (65)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
2. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
3. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527-1535.
4. A Systolic Blood Pressure Intervention Trial (SPRINT) clinical center networks. Available at: http://www1.fbo.gov/spg/HHS/NIH/NHLBI/ RFP-NHLBI-HC-09-05/SynopsisP.html. Accessed July 28, 2008.
5. Laragh JH. Modern system for treating high blood pressure based on renin profiling and vasoconstriction-volume analysis: a primary role for beta blocking drugs such as propranolol. Am J Med. 1976;61:797-810.
6. Brown MJ. Renin: friend or foe? Heart. 2007;93:1026-1033.
7. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H. The Losartan Intervention For Endpoint Reduction in Hypertension Study. Lancet. 2002;359:995-1003.
8. Cockcroft JR, Brown MJ. Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study. Lancet. 2002;359:2202.
9. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo- Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895-906.
10. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113:1213-1225.
11. NICE/BHS. CG34Hypertension: NICEguideline(alltherecommendations). Available at: http://www.nice.org.uk/guidance/CG34/niceguidance/ pdf/English. 2006. Accessed July 28, 2008.
12. Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, Lango H, Timpson NJ, Perry JR. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science. 2007;316: 1336-1341.
13. Zanchi A, Maillard M, Burnier M. Recent clinical trials with omapatrilat: new developments. Curr Hypertens Rep. 2003;5:346-352.
14. Wakerlin GE. Antibodies to renin as proof of the pathogenesis of sustained renal hypertension. Circulation. 1953;17:653-657.
15. Gross F, Lazar J, Orth H. Inhibition of the renin-angiotensinogen reaction by pepstatin. Science. 1972;175:656.
16. Haber E, Hui KY, Carlson WD, Bernatowicz MS. Renin inhibitors: a search for principles of design. J Cardiovasc Pharmacol. 1987;10(suppl 7):S54-S58.
17. Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet. 2006;368: 1449-1456.
18. Webb DJ, Manhem PJ, Ball SG, Inglis G, Leckie BJ, Lever AF, Morton JJ, Robertson JI. A study of the renin inhibitor H142 in man. J Hypertens. 1985;3:653-658.
19. Wood JM, Cumin F, Maibaum J. Pharmacology of renin inhibitors and their application to the treatment of hypertension. Pharmacol Ther. 1994; 61:325-344.
20. Wood JM, Maibaum J, Rahuel J, Grutter MG, Cohen NC, Rasetti V, Ruger H, Goschke R. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun. 2003;308: 698 -705.
21. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension. 2002;39:E1-E8.
22. Limoges D, Dieterich HA, Yeh C-M, Vaidyanathan S, Howard D, Dole WP. A study of the dose proportionality of the pharmacokinetics of the oral direct renin inhibitor aliskiren in healthy subjects. Int J Clin Pharmacol Ther. 2008;46:252-258.
23. Howard D, Dieterich HA, Yeh C, Vaidyanathan S, Dole WP. Aliskiren, a direct renin inhibitor, provides predictable steady-state pharmacoki- netics with no over-accumulation in healthy subjects. Basic Clin Pharmacol Toxicol. 2007;101:134, P216.
24. Waldmeier F, Glaenzel U, Wirz B, Oberer L, Schmid D, Seiberling M, Valencia J, Riviere GJ. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab Dispos. 2007;35:1418-1428.
25. Campbell DJ. Interpretation of plasma renin concentration in patients receiving aliskiren therapy. Hypertension. 2008;51:15-18.
26. Bohlender J, Fukamizu A, Lippoldt A, Nomura T, Dietz R, Menard J, Murakami K, Luft FC. High human renin hypertension in transgenic rats. Hypertension. 1997;29:428-434.
27. Wood JM, Schnell CR, Cumin F, Menard J, Webb RL. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens. 2005;23:417-426.
28. Azizi M, Menard J, Bissery A, Guyenne TT, Bura-Riviere A, Vaidyanathan S, Camisasca RP. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol. 2004;15:3126-3133.
29. Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol. 2007;49:1157-1163.
30. Taylor AA, Anderson DR, Arora V. Renin system suppression with the oral direct renin inhibitor aliskiren administered alone or in combination: a pooled analysis of 1093 patients with hypertension. J Am Coll Cardiol. 2007;49(suppl A):370A. Abstract 1014-170.
31. Fournier A, Achard JM, Mazouz H, Pruna A, Hottelart C, Rosa A, Fernandez L, Andrejak M. Could angiotensin II type I receptor antagonists have a superior beneficial effect than that of angiotensin II converting enzyme inhibitors with espect to the risk of cerebrovascular accident? Arch Mal Coeur Vaiss. 1999;92:997-1000.
32. Saris JJ, 't Hoen PA, Garrelds IM, Dekkers DH, den Dunnen JT, Lamers JM, Jan Danser AH. Prorenin induces intracellular signaling in cardio- myocytes independently of angiotensin II. Hypertension. 2006;48: 564-751.
33. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest. 2002;109:1417-1427.
34. Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M, Suzuki F, Nakagawa T, Nishiyama A, Inagami T. Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension. 2006;47:894-900.
35. Muller DN, Klanke B, Feldt S, Cordasic N, Hartner A, Schmieder RE, Luft FC, Hilgers KF. (Pro)renin receptor peptide inhibitor "handle- region" peptide does not affect hypertensive nephrosclerosis in Goldblatt rats. Hypertension. 2008;51:676-681.
36. Kushiro T, Itakura H, Abo Y, Gotou H, Terao S, Keefe DL. Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res. 2006;29:997-1005.
37. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose- dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005;111:1012-1018.
38. Pool JL, Schmieder RE, Azizi M, Aldigier JC, Januszewicz A, Zidek W, Chiang Y, Satlin A. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens. 2007;20:11-20.
39. Villamil A, Chrysant SG, Calhoun D, Schober B, Hsu H, Matrisciano- Dimichino L, Zhang J. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochloro- thiazide. J Hypertens. 2007;25:217-226.
40. Strasser RH, Puig JG, Farsang C, Croket M, Li J, van Ingen H. A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. J Hum Hypertens. 2007;21:780-787.
41. Drummond W, Munger MA, Rafique Essop M, Maboudian M, Khan M, Keefe DL. Antihypertensive efficacy of the oral direct Renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens. 2007;9:742-750.
42. Uresin Y, Taylor AA, Kilo C, Tschope D, Santonastaso M, Ibram G, Fang H, Satlin A. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst. 2007;8:190-198.
43. Jordan J, Engeli S, Boye SW, Le Breton S, Keefe DL. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension. 2007;49:1047-1055.
44. Verdecchia P, Calvo C, Mockel V, Keeling L, Satlin A. Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension. Blood Press. 2007;16:381-391.
45. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007;370:221-229.
46. Andersen K, Weinberger M, Egan B, Constance CM, Ali MA, Jin J, Keefe DL. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens. 2007;26:589 -599.
47. Schmieder RE, Philipp T, Guerediaga J, Gorostidi M, Smith B, Weissbach N, Maboudian M, Botha J. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. J Clin Hypertens. 2007;9(suppl A5):A182. Abstract P-436.
48. Gradman AH, Kolloch R, Meyers M, Cai J, Zhang J. Aliskiren in combination with hydrochlorothiazide is effective and well tolerated during long-term treatment of hypertension. J Clin Hypertens. 2007; 9(suppl A5):A160. Abstract P-384.
49. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the
50. antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2000;283:1967-1975.
51. Sleight P, Yusuf S, Pogue J, Tsuyuki R, Diaz R, Probstfield J. Blood- pressure reduction and cardiovascular risk in HOPE study. Lancet. 2001; 358:2130-2131.
52. Hollifield JW. Thiazide treatment of hypertension: effects of thiazide diuretics on serum potassium, magnesium, and ventricular ectopy. Am J Med. 1986;80:8 -12.
53. Hood SJ, Taylor KP, Ashby MJ, Brown MJ. The Spironolactone, Amiloride, Losartan, and Thiazide (SALT) double-blind crossovertrial in patients with low-renin hypertension and elevated aldosterone-renin ratio. Circulation. 2007;116:268-275.
54. Deleted in proof.
55. McMurray JJV, Pitt B, Latini R, Maggioni A, Solomon S, Keefe DL, Ford J, Verma A. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circulation. In press.
56. Parving H-H, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358:2433-2446.
57. Solomon S, Appelbaum E, Manning WJ, Verma A, Berglund T, Luka- shevich T, Cherif-Papst C, Carten J. The Aliskiren Left Ventricular Assessment of Hypertrophy (ALLAY) Trial. Available at: http:// www.medicalnewstoday.com/ articles/102328.php. Accessed July 28,2008.
58. Lu H, Rateri DL, Feldman DL, Jr RJ, Fukamizu A, Ishida J, Oesterling EG, Cassis LA. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest. 2008;118:984-993.
59. Primatesta P, Poulter NR. Improvement in hypertension management in England: results from the Health Survey for England 2003. J Hypertens.2006;24:1193-1200.0
60. Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H, Poulter NR. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49:839-845.
61. Alderman MH, Ooi WL, Cohen H, Madhavan S, Sealey JE, Laragh JH. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am J Hypertens. 1997;10:1-8.
62. Parikh NI, Gona P, Larson MG, Wang TJ, Newton-Cheh C, Levy D, Benjamin EJ, Kannel WB. Plasma renin and risk of cardiovascular disease and mortality: the Framingham Heart Study. Eur Heart J. 2007;28:2644-2652.
63. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559.
64. Poulter NR, Wedel H, Dahlof B, Sever PS, Beevers DG, Caulfield M, Kjeldsen SE, Kristinsson A. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo- Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet. 2005;366:907-913.
65. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, Hua T, Laragh JH. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet. 2004;363:2049-2051.